TL;DR
This study investigates how different chemotherapy regimens (5FU vs. FOLFOX) impact bone marrow tolerance and the risk of acute hematologic toxicity (HT) in rectal cancer patients undergoing intensity-modulated radiation therapy (IMRT). The findings reveal that the FOLFOX regimen leads to significantly higher rates of HT and a greater risk of severe toxicity compared to 5FU, suggesting that chemotherapy choice is a critical factor in predicting and managing radiation-induced bone marrow damage.
What Problem Does This Paper Address?
Rectal cancer treatment often involves concurrent chemoradiotherapy (CRT), a combination that can lead to acute hematologic toxicity (HT), such as low blood cell counts. This toxicity can disrupt treatment schedules and negatively impact outcomes. While radiation dose to the pelvic bone marrow (PBM) is known to correlate with HT, the influence of different chemotherapy regimens on this relationship and on the predictive power of normal tissue complication probability (NTCP) models has been unclear. Specifically, the addition of oxaliplatin (L-OHP) in the FOLFOX regimen is known to increase toxicity, but its specific impact on PBM tolerance and NTCP modeling in the context of IMRT for rectal cancer needed further investigation. This paper aims to fill this gap by comparing the effects of 5FU alone versus FOLFOX in patients receiving IMRT and concurrent chemotherapy.
Methods
The researchers recruited 128 rectal cancer patients from a prospective phase III clinical trial who received IMRT. These patients were divided into two groups based on their chemotherapy regimen: 5FU alone (58 patients) or FOLFOX (70 patients). Acute hematologic toxicity (HT), defined as grade ≥2 (HT2+) and grade ≥3 (HT3+) leukopenia, neutropenia, anemia, and thrombocytopenia, was assessed. The pelvic bone marrow (PBM) was delineated into three subsites (lumbosacral spine, ilium, and lower pelvic), and dose-volume histograms (DVHs) were generated to extract dosimetric parameters. Logistic regression was used to identify correlations between dosimetric parameters and HT. Crucially, the Lyman-Kutcher-Burman (LKB) model was employed to calculate NTCP for PBM, allowing for the estimation of complication probabilities based on radiation dose.
Datasets
The study utilized data from 128 rectal cancer patients who participated in the Chinese FOWARC multicenter, open-label, randomized phase III trial. These patients received IMRT at a single institution. The data included patient characteristics, treatment details (radiation dose, chemotherapy regimen), and hematologic toxicity assessments. No new datasets were introduced; the study relied on existing clinical trial data.
Key Insights and Ideas
- Chemotherapy is a Major Driver of Bone Marrow Toxicity: The study strongly suggests that the choice of chemotherapy regimen significantly impacts bone marrow tolerance, with FOLFOX posing a substantially higher risk of HT than 5FU.
- FOLFOX Impairs Bone Marrow Tolerance: Patients receiving FOLFOX exhibited significantly higher rates of both grade 2+ and grade 3+ hematologic toxicity, indicating a reduced tolerance of the bone marrow to chemoradiotherapy when oxaliplatin is included.
- Dosimetric Predictors Differ by Regimen: While low-dose radiation to the PBM (specifically V10 and V15 for the lower pelvic region) was predictive of HT2+ in the 5FU group, these dosimetric parameters did not show a significant correlation with HT2+ in the FOLFOX group. This suggests that the mechanisms of toxicity might differ between the regimens.
- NTCP Models Highlight Increased Risk with FOLFOX: NTCP modeling for severe HT (grade 3+) revealed a much higher predicted risk for patients on the FOLFOX regimen compared to those on 5FU, underscoring the clinical implications of the observed toxicity differences.
- PBM Acts as a Parallel Organ: The LKB model fitting, with a constrained parameter 'n' equal to 1 for both groups, suggests that the pelvic bone marrow functions as a parallel organ in terms of its response to radiation, meaning that damage to any part of the organ contributes to the overall complication risk.
Key Results
- Higher HT Rates with FOLFOX: 65.7% of FOLFOX patients experienced HT2+ compared to 37.9% of 5FU patients (p=0.008). For HT3+, the rates were 31.4% in the FOLFOX group versus 6.9% in the 5FU group (p=0.016).
- Predictive Dosimetric Parameters: In the 5FU group, PBM V15 and lower pelvic V10 and V15 were significantly correlated with HT2+. In the FOLFOX group, BMI and N classification were predictors of HT2+.
- NTCP for HT3+: The mean NTCP for HT3+ was 0.32 in the FOLFOX group, significantly higher than the 0.10 in the 5FU group (p < 0.05).
Limitations and Future Work
The authors acknowledge several limitations:
- Small Cohort Size: The study was conducted at a single institution with a relatively small number of patients, limiting the generalizability of the findings and the ability to refine models further.
- Contouring Entire Bone: The PBM was contoured as the entire bone, not just the active marrow, which could introduce variability.
- Lack of Active Marrow Information: The study did not account for the functional distribution of active bone marrow, which could be assessed using SPECT.
- Time-Varying Covariates: The statistical models used did not fully account for time-varying covariates, which could be addressed with log-linear mixed effects models.
Future work should focus on validating these findings in larger, multi-center studies. The authors suggest that chemotherapy-adapted dose constraints for the PBM should be developed for future prospective protocols, and that sparing the PBM is particularly important for patients with low BMI who are at increased risk of developing HT. Further research using more advanced modeling techniques to incorporate time-varying covariates is also warranted.
Summary updated